16,300 Shares in Merck & Co., Inc. $MRK Purchased by Dorato Capital Management

robot
Abstract generation in progress

Dorato Capital Management recently acquired 16,300 shares of Merck & Co., Inc. (NYSE:MRK) valued at approximately $1.809 million, making it the fund’s 15th-largest holding. This purchase comes amidst significant insider selling, with executives offloading over $38 million worth of shares in the last 90 days. Merck has several positive catalysts, including EU approval for Keytruda in ovarian cancer and strong Phase 3 results for an oral PCSK9 candidate, leading to a consensus “Moderate Buy” rating from analysts with an average price target of $127.13.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin